Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR) a double-blind, placebo-controlled, randomised, phase 3 trial /
Vericiguat is indicated to reduce the risk of cardiovascular death and hospitalisation for heart failure in patients with heart failure and reduced ejection fraction (HFrEF) following a recent worsening event. The aim of the VICTOR trial was to assess the effect of vericiguat in patients with HFrEF...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2025
|
| Sorozat: | LANCET
406 No. 10510 |
| Tárgyszavak: | |
| doi: | 10.1016/S0140-6736(25)01665-4 |
| mtmt: | 36319569 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/38376 |